March 12, 2009 - GE Healthcare and Lunar Division, which markets bone densitometry products, have entered into a distribution agreement with Biospace Co., in which Lunar will offer U.S. customers BIOSPACE’S InBody230 and InBody720, bioelectric impedance analyzers measuring body composition.
Biospace develops bioelectric impedance analysis (BIA) technology, and GE will be integrating BIOSPACE’S InBody products into their Lunar Bone Mineral Density portfolio, including showcasing the InBody products at primary care and metabolic health-related trade shows across the U.S.
Both products are known for their ability to measure body fat mass and segmental lean mass without the need to make estimations based on such factors as age, gender or body type. Such technology can have a positive impact on overall health by enabling patients to more effectively manage weight, and more importantly, body composition. The combination of GE’s dedication to early health and BIOSPACE’S patented Direct Segmental Multi-frequency Bioelectric Impedance Analysis will provide patients an easy and advanced solution to monitoring weight and muscle development.
GE hopes that BIOSPACE’S Inbody product line combined with GE’s distribution strength will accelerate the adoption of body composition as a standard measure in the U.S.
For more information: www.gehealthcare.com/bmd
February 22, 2018 
